Metaproterenol (alupent™ metered dose inhaler in children 5-12 years of age

William W. Storms, C. Warren Bierman, Hyman Chai, Robert J. Dockhorn, Peyton Eggleston, Elliot F. Ellis, Charles Feldman, Jordan N. Fink, Mary Pat Hemstreet, William T. Kniker, Alan Knutsen, Peter Konig, Herbert Mansmann, Sheldon Siegel, Herbert Krantman, David Tinkelman, Robert Townley, Margaret Wecker, Judith Jaeger

Research output: Contribution to journalArticle

Abstract

This multiclinic study was performed to evaluate the safety and efficacy of metaproterenol sulfate (Alupent™ metered dose inhaler in children with asthma ages 5 to 12 years. A total of 268 children completed this study according to the protocol, having received either metaproterenol or placebo for 30 consecutive days. Full spirometric testing was done pre- and postdose on Days 1 and 30 for a total duration of 6 hours on each day. The results showed that metaproterenol was consistently superior to placebo in all pulmonary function parameters measured on Days 1 and 30. This difference was statistically significant for peak values and areas under the curves for both FEV1 and FEF25-75%. There were no significant side effects noted. We conclude that metaproterenol metered dose inhaler is safe and effective in the treatment of asthma in children ages 5 to 12 years.

Original languageEnglish
Pages (from-to)369-379
Number of pages11
JournalJournal of Asthma
Volume28
Issue number5
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Metaproterenol
Metered Dose Inhalers
Asthma
Placebos
Area Under Curve
Safety
Lung

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Pediatrics, Perinatology, and Child Health

Cite this

Storms, W. W., Bierman, C. W., Chai, H., Dockhorn, R. J., Eggleston, P., Ellis, E. F., ... Jaeger, J. (1991). Metaproterenol (alupent™ metered dose inhaler in children 5-12 years of age. Journal of Asthma, 28(5), 369-379. https://doi.org/10.3109/02770909109089464

Metaproterenol (alupent™ metered dose inhaler in children 5-12 years of age. / Storms, William W.; Bierman, C. Warren; Chai, Hyman; Dockhorn, Robert J.; Eggleston, Peyton; Ellis, Elliot F.; Feldman, Charles; Fink, Jordan N.; Hemstreet, Mary Pat; Kniker, William T.; Knutsen, Alan; Konig, Peter; Mansmann, Herbert; Siegel, Sheldon; Krantman, Herbert; Tinkelman, David; Townley, Robert; Wecker, Margaret; Jaeger, Judith.

In: Journal of Asthma, Vol. 28, No. 5, 1991, p. 369-379.

Research output: Contribution to journalArticle

Storms, WW, Bierman, CW, Chai, H, Dockhorn, RJ, Eggleston, P, Ellis, EF, Feldman, C, Fink, JN, Hemstreet, MP, Kniker, WT, Knutsen, A, Konig, P, Mansmann, H, Siegel, S, Krantman, H, Tinkelman, D, Townley, R, Wecker, M & Jaeger, J 1991, 'Metaproterenol (alupent™ metered dose inhaler in children 5-12 years of age', Journal of Asthma, vol. 28, no. 5, pp. 369-379. https://doi.org/10.3109/02770909109089464
Storms WW, Bierman CW, Chai H, Dockhorn RJ, Eggleston P, Ellis EF et al. Metaproterenol (alupent™ metered dose inhaler in children 5-12 years of age. Journal of Asthma. 1991;28(5):369-379. https://doi.org/10.3109/02770909109089464
Storms, William W. ; Bierman, C. Warren ; Chai, Hyman ; Dockhorn, Robert J. ; Eggleston, Peyton ; Ellis, Elliot F. ; Feldman, Charles ; Fink, Jordan N. ; Hemstreet, Mary Pat ; Kniker, William T. ; Knutsen, Alan ; Konig, Peter ; Mansmann, Herbert ; Siegel, Sheldon ; Krantman, Herbert ; Tinkelman, David ; Townley, Robert ; Wecker, Margaret ; Jaeger, Judith. / Metaproterenol (alupent™ metered dose inhaler in children 5-12 years of age. In: Journal of Asthma. 1991 ; Vol. 28, No. 5. pp. 369-379.
@article{3e54862a0c364c16a0000bb725ab57fd,
title = "Metaproterenol (alupent™ metered dose inhaler in children 5-12 years of age",
abstract = "This multiclinic study was performed to evaluate the safety and efficacy of metaproterenol sulfate (Alupent™ metered dose inhaler in children with asthma ages 5 to 12 years. A total of 268 children completed this study according to the protocol, having received either metaproterenol or placebo for 30 consecutive days. Full spirometric testing was done pre- and postdose on Days 1 and 30 for a total duration of 6 hours on each day. The results showed that metaproterenol was consistently superior to placebo in all pulmonary function parameters measured on Days 1 and 30. This difference was statistically significant for peak values and areas under the curves for both FEV1 and FEF25-75{\%}. There were no significant side effects noted. We conclude that metaproterenol metered dose inhaler is safe and effective in the treatment of asthma in children ages 5 to 12 years.",
author = "Storms, {William W.} and Bierman, {C. Warren} and Hyman Chai and Dockhorn, {Robert J.} and Peyton Eggleston and Ellis, {Elliot F.} and Charles Feldman and Fink, {Jordan N.} and Hemstreet, {Mary Pat} and Kniker, {William T.} and Alan Knutsen and Peter Konig and Herbert Mansmann and Sheldon Siegel and Herbert Krantman and David Tinkelman and Robert Townley and Margaret Wecker and Judith Jaeger",
year = "1991",
doi = "10.3109/02770909109089464",
language = "English",
volume = "28",
pages = "369--379",
journal = "Journal of Asthma",
issn = "0277-0903",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Metaproterenol (alupent™ metered dose inhaler in children 5-12 years of age

AU - Storms, William W.

AU - Bierman, C. Warren

AU - Chai, Hyman

AU - Dockhorn, Robert J.

AU - Eggleston, Peyton

AU - Ellis, Elliot F.

AU - Feldman, Charles

AU - Fink, Jordan N.

AU - Hemstreet, Mary Pat

AU - Kniker, William T.

AU - Knutsen, Alan

AU - Konig, Peter

AU - Mansmann, Herbert

AU - Siegel, Sheldon

AU - Krantman, Herbert

AU - Tinkelman, David

AU - Townley, Robert

AU - Wecker, Margaret

AU - Jaeger, Judith

PY - 1991

Y1 - 1991

N2 - This multiclinic study was performed to evaluate the safety and efficacy of metaproterenol sulfate (Alupent™ metered dose inhaler in children with asthma ages 5 to 12 years. A total of 268 children completed this study according to the protocol, having received either metaproterenol or placebo for 30 consecutive days. Full spirometric testing was done pre- and postdose on Days 1 and 30 for a total duration of 6 hours on each day. The results showed that metaproterenol was consistently superior to placebo in all pulmonary function parameters measured on Days 1 and 30. This difference was statistically significant for peak values and areas under the curves for both FEV1 and FEF25-75%. There were no significant side effects noted. We conclude that metaproterenol metered dose inhaler is safe and effective in the treatment of asthma in children ages 5 to 12 years.

AB - This multiclinic study was performed to evaluate the safety and efficacy of metaproterenol sulfate (Alupent™ metered dose inhaler in children with asthma ages 5 to 12 years. A total of 268 children completed this study according to the protocol, having received either metaproterenol or placebo for 30 consecutive days. Full spirometric testing was done pre- and postdose on Days 1 and 30 for a total duration of 6 hours on each day. The results showed that metaproterenol was consistently superior to placebo in all pulmonary function parameters measured on Days 1 and 30. This difference was statistically significant for peak values and areas under the curves for both FEV1 and FEF25-75%. There were no significant side effects noted. We conclude that metaproterenol metered dose inhaler is safe and effective in the treatment of asthma in children ages 5 to 12 years.

UR - http://www.scopus.com/inward/record.url?scp=0025925054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025925054&partnerID=8YFLogxK

U2 - 10.3109/02770909109089464

DO - 10.3109/02770909109089464

M3 - Article

C2 - 1938771

AN - SCOPUS:0025925054

VL - 28

SP - 369

EP - 379

JO - Journal of Asthma

JF - Journal of Asthma

SN - 0277-0903

IS - 5

ER -